Shire Looks To Europe to Expand ADHD Franchise, But U.S.-Style Success Will Be Tough
Executive Summary
Shire Pharmaceuticals PLC built the backbone of its $3 billion business on the U.S. attention deficit hyperactivity disorder (ADHD) market. It now faces an uphill battle as it tries to expand the franchise by tapping into Europe, as part of a broader international push.
You may also be interested in...
On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.
Shire CEO Angus Russell On The Value Proposition For Drugs
Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”